Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

JDOC

JPMorgan Healthcare Leaders ETF (JDOC)

Rating:66Neutral
Price Target:$65.00â–¼(-3.35% Downside)

JDOC, the JPMorgan Healthcare Leaders ETF, is built around high-quality healthcare giants like Merck, Novartis, Johnson & Johnson, and AstraZeneca, whose strong financial performance, solid pipelines, and positive earnings outlooks are key drivers of the fund’s solid overall rating. These strengths are partly offset by risks such as high valuations, leverage and cash flow challenges in names like Eli Lilly, Thermo Fisher, and UnitedHealth, plus some bearish or overbought technical signals, which add volatility and temper the fund’s appeal. The main risk factor is the ETF’s concentration in the healthcare sector, meaning its performance is closely tied to industry-specific trends and regulatory developments.

Positive Factors
Strong Year-to-Date PerformanceThe fund has delivered strong gains so far this year, suggesting its strategy has worked well in the recent market.
Leading Healthcare HoldingsSeveral top positions like AbbVie, Eli Lilly, UnitedHealth, Merck, and Johnson & Johnson have shown strong performance, helping drive the ETF’s returns.
Global Healthcare ExposureWhile most holdings are in the U.S., the fund also invests in major healthcare companies from Switzerland, the UK, Germany, Japan, and Israel, adding some international diversification.
Negative Factors
High Sector ConcentrationWith most assets in healthcare, the ETF is heavily exposed to risks specific to that one sector.
Mixed Performance Among Top HoldingsSome key positions, such as AstraZeneca and Intuitive Surgical, have shown weaker performance, which can drag on overall returns.
Above-Average Expense RatioThe fund’s fee is relatively high for an ETF, which means more of the returns are eaten up by costs over time.

JDOC vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%SPY+14.55%JDOC+18.25%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
10.02M
Region
Global
Expense Ratio
0.65%
Beta
0.45
Issuer
JPMorgan
Inception Date
Nov 01, 2023
Dividend Yield
0.76%
Asset Class
Equity
Index Tracked
No Underlying Index

JDOC Summary

JDOC, the JPMorgan Healthcare Leaders ETF, focuses on the global healthcare theme rather than tracking a specific index. It invests mainly in U.S. healthcare companies, including well-known names like Johnson & Johnson and Eli Lilly, along with drug makers, medical device firms, and health insurance providers. Someone might invest in JDOC to tap into long-term growth driven by aging populations, new medicines, and rising healthcare spending, while still spreading money across many companies in the sector. A key risk is that it is heavily concentrated in healthcare, so its value can rise or fall sharply if that sector has problems.

How much will it cost me?

This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed and focused on a specialized healthcare sector, which typically costs more to run than broad, passive index funds.

What would affect this ETF?

JDOC could benefit from aging populations, rising global healthcare spending, and continued innovation in drugs and medical technology from major holdings like AbbVie, Eli Lilly, and Johnson & Johnson. On the downside, changes in government healthcare policies, drug pricing rules, or global economic slowdowns could hurt profits for large insurers and pharmaceutical companies such as UnitedHealth and Merck, which would weigh on the ETF’s performance.

JDOC Top 10 Holdings

JDOC is leaning heavily on big pharma and healthcare giants, with AbbVie, Eli Lilly, and Johnson & Johnson doing most of the heavy lifting as their shares keep rising and sentiment stays upbeat. UnitedHealth and Thermo Fisher add steady, growth-oriented exposure, though UnitedHealth’s recent stretch has been more mixed. Merck is another quiet engine, contributing solidly despite occasional bumps. On the weaker side, AstraZeneca and Intuitive Surgical have been lagging, occasionally acting as a brake on returns. Overall, it’s a globally diversified but clearly healthcare-focused portfolio anchored in large, established names.

JDOC top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
LLYLLYEli Lilly & Co8.73%$881.06K$1.36T41.12%72Outperform
ABBVABBVAbbVie8.35%$843.05K$521.50B27.01%66Neutral
UNHUNHUnitedHealth5.24%$529.06K$365.09B22.54%72Outperform
JNJJNJJohnson & Johnson4.69%$473.61K$687.89B46.35%78Outperform
CH:NOVNCH:NOVNNovartis AG4.50%$454.50KCHF 245.40B26.78%80Outperform
TMOTMOThermo Fisher4.42%$446.42K$259.44B20.70%72Outperform
AZNAZNAstraZeneca――――80Outperform
MRKMRKMerck & Company3.51%$354.26K$364.26B59.00%80Outperform
DHRDHRDanaher2.85%$287.78K$163.94B5.34%75Outperform
ISRGISRGIntuitive Surgical2.63%$265.22K$153.77B-21.56%78Outperform

JDOC Technical Analysis

Technical Analysis SentimentPositive
Last Price67.25

Price Trends

50DMA62.73Positive
100DMA62.20Positive
200DMA59.40Positive

Market Momentum

MACD1.43Negative
RSI66.61Neutral
STOCH82.84Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JDOC, the sentiment is Positive. The current price of 67.25 is above the 20-day moving average (MA) of 65.35, above the 50-day MA of 62.73, and above the 200-day MA of 59.40, indicating a bullish trend. The MACD of 1.43 indicates Negative momentum. The RSI at 66.61 is Neutral, neither overbought nor oversold. The STOCH value of 82.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JDOC.

JDOC Peer Comparison

Comparison Results

JDOC against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
JDOCJDOC$67.25$65.00(-3.35% Downside)$10.02M0.65%66Neutral
MEDIMEDI$36.34$46.47(27.88% Upside)$44.15M0.80%62Neutral
TMEDTMED$34.80$54.70(57.19% Upside)$41.60M0.44%60Neutral
MEDXMEDX$38.01$44.46(16.98% Upside)$17.77M0.85%65Neutral
BMEDBMED$36.32$40.35(11.10% Upside)$14.56M0.55%65Neutral
HLTHHLTH$26.09$38.81(48.74% Upside)$11.14M0.75%55Neutral

Performance Comparison

-10%0%10%20%JDOCMEDITMEDMEDXBMEDHLTHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JDOC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JDOCJPMorgan Healthcare Leaders ETF67.2510.6618.84%
MEDIHarbor Health Care ETF36.344.9115.61%
TMEDT. Rowe Price Health Care ETF34.805.8019.98%
MEDXHorizon Kinetics Medical ETF38.015.5917.25%
BMEDFuture Health ETF36.327.3725.46%
HLTHTema Healthcare AI ETF26.090.783.09%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.